Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Authors: María‐Victoria Mateos, Michèle Cavo, Joan Bladé, Meletios Α. Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lúcio, Zsolt Nagy, Luděk Pour, Mark Cook, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung‐Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Maria Krevvata, Ying Chen, Jianping Wang, Anupa Kudva, Jon Ukropec, Susan Wróblewski, Ming Qi, Rachel Kobos, Jesús F. San Miguel - The Lancet 2019 cited by 438